Duavive (conjugated oestrogens/ bazedoxifene) approved for treatment of menopausal symptoms

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

July 04, 2016: Duavive (conjugated oestrogens/ bazedoxifene) is licensed for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus who are at least one year after their last period, when progestin-containing therapy is not suitable.

Duavive combines conjugated oestrogens with the selective oestrogen receptor modulator (SER...